^
Association details:
| Biomarker: | CD20 positive |
|---|---|
| Cancer: | Non-Hodgkin’s Lymphoma |
| Drug: | Ruxience (rituximab-pvvr) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
RUXIENCE (rituximab-pvvr) is a CD20-directed cytolytic antibody indicated for the treatment of...Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line
cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.
